AbstractBackgroundThe NIA‐AA research framework group and the IWG both agree that abnormal AD biomarkers are necessary for the diagnosis of AD; however, the groups disagree on the appropriate definition of Alzheimer’s disease. The NIA‐AA framework argues that a CU A+T+ individual has AD pathology and therefore has the disease. The IWG argues that such an individual should be labeled “at risk for AD” because both abnormal biomarkers and clinically significant impairment are required for an AD diagnosis.MethodThe major IWG argument against a biological‐only definition of AD is that some CU A+T+ individuals will die of other causes without experiencing overt symptoms (MCI or dementia) in their lifetime. However, the same statement can be made about any other disease in medicine. The question therefore must be how often will CU A+T+ individuals die without experiencing dementia.ResultMany studies have examined rates of cognitive decline in CU A+ relative to CU A‐ (fewer studies in CU A+T+ vs CU A‐T‐). Studies have examined the risk of incident MCI/dementia in CU A+ relative to CU A‐ (fewer in CU A+T+ vs CU A‐T‐). Relative risk indicates likelihood of an outcome in a particular risk group relative to a reference group; it does not indicate the likelihood in percentage terms that an individual will experience an outcome in their lifetime. It is lifetime risk (i.e., absolute risk) that is needed to address the current controversy and to our knowledge only 2 published studies have estimated lifetime risk associated with AD biomarkers. A recent Mayo Clinic Study of Aging analysis examined lifetime risk of dementia associated with varying levels of amyloid PET, APOE and sex. Among APOE ε4 carriers with high amyloid PET SUVR, remaining lifetime risk of dementia at age 75 years was 76% for women and 64% for men. Lifetime risk of CU A+T+ remains to be determined, however.ConclusionThe major discordance between the NIA‐AA framework and the IWG (the definition of AD) points to the question, how risky is the CU A+T+ state? Accurate estimates of lifetime risk from population‐based studies are needed to address this question.
ISPAD
clinical practice consensus guidelines 2022: Management of children and adolescents with diabetes requiring surgery
AbstractBackgroundAlzheimer’s disease (AD) lacks a fast, easy, reliable, and inexpensive method of diagnosis. Currently, diagnosis is based on time‐consuming behavioral tests and the exclusion of other potential causes of impairment. Several biomarkers show good or promising diagnostic performance (e.g. CSF, tau PET, MRI, blood), but are either expensive, invasive, or still in development and while some can detect preclinical disease stages, all appear slow to change relative to the rate of cognitive decline. Here we develop a prototype diagnostic classifier based on novel metrics of brain activity in resting state electroencephalography (EEG) that correlates well with mental status.MethodArchival resting‐state EEG recordings of older adults (N=248) came from a memory clinic and university‐based clinic with a range of clinical diagnoses including subjective cognitive impairment (SCI), mild cognitive impairment (MCI), and dementia, representing AD, vascular dementia, and Lewy body dementia, TBI, and depression. We developed XGBoost classifiers to detect AD using EEG, age, and sex under increasingly challenging conditions. We computed metrics of periodic and aperiodic brain activity using the FOOOF algorithm. Furthermore, we developed a novel technique called [Banded Fractal Variability], which yields a set of features based on fluctuations in the fractal dimension within canonical frequency bands. We trained classifiers using cross‐validation to avoid overfitting during hyperparameter selection.ResultAlong with ROCAUC, we report an optimal sensitivity, specificity, and accuracy for the point on the ROC curve that maximizes Youden’s j. The classification tasks were healthy vs. probable AD (ROCAUC = 98%, sensitivity = 90%, specificity = 99%, accuracy = 96%), SCI vs. mild AD (ROCAUC = 89%, sensitivity = 76%, specificity = 87%, accuracy = 84%), and AD vs. other pathologies (no AD diagnosis) in MCI and dementia patients (ROCAUC = 82%, sensitivity = 72%, specificity = 87%, accuracy = 80%). All ROCAUC values were stronger than would be expected by chance (ps < 0.001).ConclusionThese preliminary results suggest that AD could be diagnosed in the clinic on the basis of machine‐learning classifiers and resting‐state EEG. Furthermore, they demonstrate that [Banded Fractal Variability] carries clinically‐relevant information about AD.
Plasma Biomarkers of Amyloid and Neurodegeneration predictive of Neuropathologic Scales of Cerebrovascular Disease
AbstractBackgroundBlood‐based biomarkers of amyloid and neurodegeneration are increasingly used in clinical trials and entering clinical use. Differentially mapping the plasma markers to post‐mortem neuropathology in a community‐based sample is critical for interpretation.MethodWe identified 64 Mayo Clinic Study of Aging (MCSA) participants with antemortem plasma markers (Aβ42, Aβ40, NfL, T‐tau, Aβ42/40 ratio) measured on the Quanterix Simoa HD‐1 analyzer and with postmortem neuropathologic assessments of Alzheimer’s pathology (Braak tangle stage, Thal phase, neuritic plaque burden) and cerebrovascular pathology (Strozyk scale focused on macrovascular brain changes and Kalaria scale focused on detailed micro‐ and macro‐ vascular brain changes). Weighted linear regression models with adjustment for time between plasma markers and death were conducted with exact permutation tests to evaluate the relationships between antemortem plasma and postmortem neuropathology markers.ResultHigher plasma NfL levels and Aβ42/40 ratio were associated with both cerebrovascular neuropathologic scales (p<0.05) but were not associated with Braak neurofibrillary tangle stage, neuritic plaque score, or Thal stage (p>0.5). Plasma T‐tau was not associated with any pathological assessment. Plasma Aβ42/40 and NfL explained up to 18% of the variability in cerebrovascular neuropathologic scales.ConclusionIn this community sample of participants predominantly without dementia, plasma markers for amyloid (Aβ42/40) and neurodegeneration (NfL) were associated with cerebrovascular neuropathology at autopsy. NfL is a non‐specific marker of brain injury, therefore, its association with cerebrovascular neuropathology was in the expected direction. The association between greater cerebrovascular neuropathology and elevated Aβ42/40 requires further investigation. These findings provide evidence that cerebrovascular disease may significantly influence levels of plasma biomarkers proposed for Alzheimer’s disease. This information will be important to consider for accurate clinical interpretation of the proposed biomarkers.
Baseline and Longitudinal Ioflupane SPECT Findings in DLB and MCI‐LB
AbstractBackgroundReduced striatal uptake on ioflupane SPECT is considered an indicative biomarker for Dementia with Lewy Bodies (DLB), and has been proposed as an indicative biomarker for Mild Cognitive Impairment with Lewy Bodies (MCI‐LB). Little data exists on the profile of uptake on key striatal regions of interest (ROIs) in DLB or MCI‐LB.MethodParticipants with DLB or MCI‐LB at baseline based on the presence of ≥2 core clinical DLB features, and ≥2 ioflupane SPECT scans performed approximately annually, were identified from the Mayo ADRC database. Minimum brain laterality z‐score values for the putamen (whole, anterior and posterior), caudate and striatum were determined using DaTQUANT 2 software. Baseline clinical and scan data was used for all analyses, and the annualized minimum putamen z‐change was determined on serial scans. The scan was considered abnormal if the minimum putamen z‐score was <‐0.98 based on clinicopathologic data.Result27 participants were included (21 DLB and 6 MCI‐LB, 96% male). Compared to MCI‐LB, DLB had a lower mean MoCA score and a trend toward a higher UPDRS score compared to MCI‐LB; there were no statistically significant differences in age, sex, onset age or duration of cognitive decline, or presence of other core DLB features. The majority (89%) had an abnormal scan at baseline. All ROI z‐scores showed the expected general trend of DLB<MCI‐LB, and the annualized z‐change was more negative in DLB, but none of the findings reached statistical significance.ConclusionThese findings suggest in MCI‐LB and DLB that 1) an abnormal ioflupane SPECT scan is frequently present at diagnosis, 2) z‐scores become more negative over time, and 3) the annualized z‐change is similar. Similar findings in larger cohorts would support the use of ioflupane SPECT as a biomarker in both MCI‐LB and DLB clinical trials.
Latent space projection of brain FDG‐PET creates a powerful classifier for neurodegenerative diseases
AbstractBackgroundFluorodeoxyglucose positron emission tomography (FDG‐PET) is an established modality for differential diagnosis of dementia. Deriving phenotypic signatures from FDG‐PET via machine learning is challenging due to the high dimensional nature of brain images relative to the generally small number of labeled examples available for training, the class imbalance among those labels, and the cooccurrence of multiple pathologies. In this study, we developed a multi‐class, multi‐label framework to address these challenges.MethodA database of clinically acquired PET/CT images from 3,000 unique patients was used to develop a latent space model using matrix decomposition. This model was then applied to images from a separate cohort of Mayo Clinic Alzheimer’s Disease Research Center participants (n=1,745) labeled as cognitively unimpaired (CU) (n=1,436) or with the following potentially co‐occurring phenotypes: Alzheimer’s disease (AD) (n=165), Lewy body dementia (DLB) (n=92), behavioral variant frontotemporal dementia (bvFTD) (n=43), semantic (svPPA) (n=10) and logopenic (lvPPA) (n=13) variant PPA, and posterior cortical atrophy (PCA) (n=17). A k‐nearest neighbors classifier that is robust to these imbalanced and overlapping labels was then trained on these examples. The resulting classifier was evaluated by area under receiver‐operator characteristic curve (ROC‐AUC) via leave one out cross validation, using clinical diagnosis as the gold standard.ResultROC curves and AUC scores for each phenotype are illustrated in Fig. 1a. Because the classifier is based on a k‐nearest neighbors connectivity matrix, it has a convenient graphical representation, where images are nodes and edges are drawn between an image and its set of nearest neighbors in latent space. A self‐organizing force directed graph constructed in this way is illustrated in Fig 1b, highlighting the strong separation of CU and degenerative images, as well as the segregation of each phenotype within the neurodegenerative region of the graph.ConclusionIn this study, we developed a machine learning framework for classification of neurodegenerative disease based on k‐nearest neighbor analysis in a low dimensional latent space projection of FDG‐PET images. By leveraging low‐dimensional representations and k‐nearest neighbors analysis, this framework is robust in multi‐class, multi‐label tasks with strong class imbalance and provides a highly interpretable graphical representation.
Which NODDI implementation is nicest for diffusion MRI?
AbstractBackgroundNeurite Orientation Dispersion and Density Imaging (NODDI) is becoming increasingly common as multiband acceleration becomes available for clinical scanning, but fitting the model can be extremely slow. Since the release of the original MATLAB implementation in 2012, three alternatives have become popular: Accelerated Microstructure Imaging via Convex Optimization (AMICO), the Microstructure Diffusion Toolbox (MDT), and the CUDA Diffusion Modelling Toolbox (cuDIMOT). They accelerate fitting through reformulation and/or using GPUs, but the implementation differences raise the question of which approach is best. To our knowledge all previous comparisons lacked knowledge of the true values and used the original implementation as the nominally correct one, with in vivo data. We remedy that using simulations with known NODDI values, in addition to in vivo scans.MethodWe created a software phantom with Neurite Density Index (NDI) values linearly increasing from 0.1 to 1.0 in x, Orientation Dispersion (ODI) from 0 to 1 in y, and Isotropic water Volume Fraction (ISOVF) from 0 to 0.9 in z. We simulated five scans using the ADNI3 advanced diffusion MRI protocol. The phantom had 20 voxels in each direction, and the fiber bundle principal direction randomly varied between the simulations. The simulations were fit by the original, AMICO, MDT, and cuDIMOT implementations, and root mean square errors were calculated as shown in Table 1. A discrepancy measure was also calculated using the brain voxels of three in vivo human scans acquired using the same protocol on a Siemens Prisma, substituting the original implementation’s values for the truth since the latter is unknown for in vivo scans.ResultcuDIMOT had the least error (for ODI < 0.8) and was fastest. The original implementation was a close second in accuracy but much slower. cuDIMOT’s ODI underestimation can be corrected with a transfer function in the noise‐free case, but that approach fails with actual scans.ConclusionThe original or cuDIMOT implementations should be used, with cuDIMOT the favorite when at least one CUDA‐capable GPU is available and the number of scans are large. Correcting cuDIMOT’s ODI underestimation using a different initialization or form of Dawson’s integral should be investigated.
A standardized protocol for detection of Amyloid Related Imaging Abnormality (ARIA) on 3T Philips Magnetic Resonance Imaging (MRI)
AbstractBackgroundARIA is a common side effect of aducanumab, the first anti‐amyloid pharmacotherapy approved by the US Food and Drug Administration (FDA) to treat Alzheimer’s disease. Regular MRI is required by FDA to detect and monitor different forms of ARIA during initiation of therapy. MRI protocols must be a) high resolution to detect abnormalities with high sensitivity, b) fast to accommodate workflow and ensure patient compliance and c) standardized to maximize data acquisition consistency across sites. Based on a vendor agnostic protocol recommendation by Benzinger et al (CTAD 2021), we propose specific parameters for 3T Philips systems, for an accelerated and enhanced protocol.MethodThe protocol was developed on a 3T Philips Elition X scanner, using 32‐channel head coil, and included 3D T1, 3D FLAIR, 2D DWI, 2D T2* and multi echo 3D Susceptibility Weighted Imaging (SWI) sequences.ResultAcquisition voxel resolution of 3D T1, 3D FLAIR, T2* and DWI matches current recommendations. 3D SWI resolution is 0.7x0.7x2mm. Compressed‐SENSE (C‐SENSE) acceleration is applied on 3D T1, 3D FLAIR, T2* and 3D SWI. SENSE is applied on DWI (Figure 1). Total acquisition time including the additional 3D SWI scan is 11 minutes, 6 minutes faster than the original recommendation. Qualitative assessment of images showed high signal‐to‐noise and contrast‐to‐noise. Images were free of acceleration related artifacts. Automated slice prescription localizer ensures better reproducibility for longitudinal assessment.ConclusionImaging protocol standardization is necessary to ensure consistent accuracy for diagnosing ARIA. Broad recommendations leave room for variability, therefore specific parameters are needed to achieve cross‐platform standardization. Our protocol is applicable for 3T Philips systems with compressed‐SENSE capability and 32‐channel head coil. The recommended C‐SENSE values maintain image quality with shorter exam time. This is more comfortable for patients and easier to fit into the workflow. The higher sensitivity of SWI can improve thresholds for therapy monitoring and provide additional quantitative measurements.
The Neurofilament Surveillance Project (NSP): A biomarker study to sample blood quarterly in familial frontotemporal lobar degeneration
AbstractBackgroundIn familial frontotemporal lobar degeneration (f‐FTLD), plasma levels of neurofilament light (NfL) are elevated at least two years prior to symptom onset and predict future clinical status. The Neurofilament Surveillance Project (NSP), an actively recruiting observational study, seeks to obtain higher resolution data of temporal changes in plasma NfL to better understand its clinical utility in f‐FTLD interventional trials. The NSP is a pre‐competitive collaboration sponsored by the Bluefield Project to Cure FTD and funded by biotechnology and pharmaceutical companies and nonprofit organizations.MethodParticipants must be members of families with disease‐causing mutations in C9orf72, MAPT or GRN and enrolled in the ALLFTD natural history study. Up to 335 participants, with roughly equal representation across mutation type, provide plasma quarterly for 3 years (4355 samples total) to enable the observation of peripheral NfL levels longitudinally during disease onset and progression. Plasma is collected by certified mobile research nurses during remote visits, and NfL is measured in batch at least every 6 months. NfL measurements from one plasma aliquot per draw will be correlated with annual assessments obtained in the ALLFTD study, including measures of disease severity (CDRÒ+NACC‐FTLD, CGI, etc.), cognitive function from the UDS Neuropsychology Battery, and volumetric MRI data. Additional plasma aliquots are reserved for future analyses of other biomarkers during the course of the study; another subset of aliquots is reserved to share with interested investigators after the study ends.ResultAs of 1/19/22, the NSP had enrolled 161 participants, including 62 from C9orf72 kindreds, 60 from MAPT kindreds, and 28 from GRN kindreds. One‐hundred forty‐five participants had completed their initial visit, and 109 had completed more than 3, and up to 5, quarterly blood draws. Enrollment and study visits are ongoing despite COVID‐related limitations.ConclusionThe quarterly blood sampling from this study, combined with annual comprehensive clinical assessments through the ALLFTD natural history study, will enable a more detailed understanding of when and how NfL levels change during phenoconversion and/or disease progression in f‐FTLD mutation carriers. These data will be especially informative in the context of the targeted investigational therapeutics for f‐FTLD now entering clinical trials.
Event‐related‐potentials are sensitive and reliable EEG biomarkers for mild cognitive impairment: A longitudinal study
AbstractBackgroundEvent‐related‐potentials (ERPs) during cognitive tasks are sensitive measures of cognitive decline [1]‐[2] and could quantitatively measure the trajectory of disease progression or response to clinical interventions. In this longitudinal study, we aimed to compare ERPs between individuals with mild cognitive impairment (MCI) and controls, and to demonstrate the test‐retest reliability of ERP measures to assess their potential utility for future observational studies and treatment trials.MethodsParticipants included individuals with mild cognitive impairment (MCI, n=31) and healthy controls stratified by age: HC2 (n=46, 40‐60 yrs.), HC3 (n=56, 60‐90 yrs.). ERPs during attention, image recognition, and verbal memory tasks were recorded using a wireless EEG to determine amplitudes and latencies of the P200 and late positive potential (LPP) ERP components in response to target (memorized) and non‐target (novel) stimuli. Differences between MCI and HC3 groups were characterized at the initial visit, and longitudinal changes in ERP components were determined at 1‐year follow‐up for both groups. Reliability of ERP measures was demonstrated by computing intraclass correlation coefficient (ICC) measures of test‐retest variability in all healthy controls (HC2 and HC3) from initial visit to 1‐year follow‐up.ResultsAt the initial visit, the MCI group demonstrated reduced LPP amplitude (Hedges‐g=0.8, p=10‐3) and delayed P200‐latency (Hedges‐g=0.89, p=10‐4) when compared to HC3. Reliability in healthy controls was high for LPP (0.85 and 0.75 for target and non‐target stimuli, respectively) and moderate for P200‐latency (0.67 and 0.53 for target and non‐target stimuli, respectively), without longitudinal changes after 1‐year follow‐up. Individuals with MCI demonstrated increased P200‐latency (Hedges‐g= 1.05, p=0.02, df=8).ConclusionsIndividuals with MCI demonstrated quantifiable memory ERP deficits at baseline with detectable change in the P200 component at 1‐year follow‐up, demonstrating that ERPs are sensitive measures for quantifying mild cognitive impairment. Test‐retest reliability of these measures was good or moderate after 1‐year, supporting their feasibility for longitudinal monitoring of patients during disease progression or quantifying the cognitive impact of potential interventions.